Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug

benzinga.com/markets/biotech/25/06/45799258/gileads-hiv-pipeline-gains-traction-with-upcoming-fda-decision-for-hiv-1-drug

In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.’s (NASDAQ:GILD) New Drug Application (NDA) submissions for lenacapavir — the company’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis…

This story appeared on benzinga.com, 2025-06-05 17:09:45.
The Entire Business World on a Single Page. Free to Use →